1.

HBV相关HCC患者Wnt5b mRNA相对表达水平与临床病理参数间的关系

Association between Wnt5b mRNA expression and clinicopathological parameters in HBV-related HCC patients (n=100)

Clinical parameters		n	Low	High	χ2	P
*We define metastasis as recurrence within 6 months postoperatively, presence of lymph node or extrahepatic invasion, and presence of cancer embolus (in the portal vein, biliary tract or hepatic vein). #6 patients of cohort 1 were lost to follow-up.
Gender	Male	90	45 (50.0%)	45 (50.0%)	0.360	0.548
	Female	10	6(60.0%)	4 (40.0%)
Age (years)	< 60	85	40 (47.1%)	45 (52.9%)	3.522	0.061
	≥60	15	11(73.3%)	4 (26.7%)
Alpha-fetoprotein	< 400 μg/L	59	31 (52.5%)	28 (47.5%)	0.137	0.711
	≥400 μg/L	41	20 (48.8%)	21 (51.2%)
Cirrhosis	Positive	72	38 (52.8%)	34 (47.2%)	0.325	0.568
	Negative	28	13 (46.4%)	15 (53.6%)
Tumor number	1	79	43 (54.4%)	36 (45.6%)	1.771	0.183
	> 1	21	8 (38.1%)	13 (61.9%)
Tumor size(cm)	≤5.0 cm	53	32 (60.4%)	21 (39.6%)	3.968	0.046
	> 5.0 cm	47	19 (40.4%)	28 (59.6%)
Tumor capsule	Positive	74	37 (50.0%)	37 (50.0%)	0.114	0.736
	Negative	26	14 (53.8%)	12 (46.2%)
Differentiation	Well	13	7 (53.8%)	6 (46.2%)	2.226	0.329
	Mederate	61	34 (55.7%)	27 (44.3%)
	Poor	26	10 (38.5%)	16 (61.5%)
TNM stage	Ⅰ+Ⅱ	46	29 (63.0%)	17 (37.0%)	4.944	0.026
	Ⅲ+Ⅳ	54	22 (40.7%)	32 (59.3%)
BCLC stage	A	43	31 (72.1%)	12 (27.9%)	13.444	0.001
	B	9	3 (33.3%)	6 (67.7%)
	C	48	17 (35.4%)	31 (64.6%)
Microvascular invasion	Positive	33	13 (39.4%)	20 (60.6%)	2.655	0.103
	Negative	67	38 (56.7%)	29 (43.3%)
Portal vein tumor thrombosis	Positive	23	10 (43.5%)	13 (56.5%)	0.676	0.411
	Negative	77	41 (53.2%)	36 (46.8%)
Metastasis*	Positive	51	19 (37.3%)	32 (62.7%)	7.869	0.005
	Negative	49	32 (65.3%)	17 (34.7%)
Recurrence#	Positive	52	21 (40.4%)	31 (59.6%)	7.667	0.006
	Negative	42	29 (69.0%)	13 (31.0%)
Recurrence-free survival (month)#	≤12	35	12 (34.3%)	23 (65.7%)	8.005	0.005
	> 12	59	38 (64.4%)	21 (35.6%)